| Trial ID: | L0614 |
| Source ID: | NCT01328470
|
| Associated Drug: |
Clopidogrel, Cilostazol
|
| Title: |
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
|
| Acronym: |
CKD
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Stable Angina
|
| Interventions: |
DRUG: Clopidogrel, cilostazol
|
| Outcome Measures: |
Primary: The differences of platelet aggregation according to the anti-platelet therapy., Platelet function was assessed with light transmittance aggregometry and the VerifyNowTM P2Y12 assay. High on-treatment platelet reactivity was defined as 5 μmol/L of ADP-induced Aggmax \> 50%. Inhibition of platelet aggregation (IPA) was defined as the percent decrease in aggregation values obtained at baseline and after treatment. VerifyNow-P2Y12 assay results are also assessed and expressed in P2Y12 reaction units (PRUs) and the percentage of inhibition., 14 days | Secondary: Changes of platelet activation markers according to the anti-platelet therapy, Markers of platelet activation (soluble CD40 ligand \[sCD40L\] and soluble P-selectin \[sP-selectin\]) were assessed at baseline and after 14 days of anti-platelet therapy., 14 days
|
| Sponsor/Collaborators: |
Sponsor: Kyunghee University Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
85
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-09
|
| Completion Date: |
2010-08
|
| Results First Posted: |
|
| Last Update Posted: |
2011-04-04
|
| Locations: |
Kyung Hee University, Seoul, 130-702, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01328470
|
